Early menopause, surgical menopause, ADHD, endometriosis, breast cancer history, diabetes, and what the evidence means for women around the world.
A 1-minute view of what this section covers. Tap any item to read the full discussion.
Guidelines frame HT in POI as prevention for cardiovascular disease, type 2 diabetes, and osteoporosis, at higher doses than standard menopause treatment, continuing until usual menopause age (~50).
Read full discussion →Continuous combined estrogen-progestogen therapy is preferred because unopposed systemic estrogen is the primary concern for recurrence and malignant transformation. Endometriosis was associated with 7.5-fold higher surgical menopause rate.
Read full discussion →Only 4% of studies were nationally representative, only 17.5% used STRAW+10 criteria, and severity/burden data are scarce. The data-quality gap is itself a finding.
Read full discussion →In the WHAM prospective cohort (104 RRSO + 102 controls), HRT users showed lumbar spine loss of only 2.3% versus 7.8% in non-users. HRT did not prevent or treat depression or anxiety.
Read full discussion →In Nigeria, one combined HRT product cost 260 minimum-wage days for a 2-month supply. BMS guidelines were authored for resource-rich, predominantly Caucasian populations.
Read full discussion →Every woman's menopause is shaped by her body, her medical history, her culture, and her healthcare system. This section addresses the populations for whom general menopause guidance must be modified — and the global contexts where access to care is itself a barrier.
If your ovaries stopped functioning before age 40, or if you experienced early menopause between ages 40 and 45, the management approach is fundamentally different from standard menopause care.
ADHD is frequently underdiagnosed in women, and hormonal changes during perimenopause can exacerbate or unmask symptoms. The overlap between ADHD and perimenopause symptoms — brain fog, concentration difficulty, mood swings, emotional dysregulation — is substantial. The key distinction is timing: ADHD symptoms are typically present from childhood, while perimenopause-linked symptoms emerge in midlife (125).
Emerging, sample-specific evidence suggests women with ADHD may have elevated vulnerability to hormone-related mood symptoms and cardiometabolic risk during perimenopause — but these signals come from clinically diagnosed cohorts, self-reported advocacy-platform surveys, and specialty-clinic samples rather than population-prevalence estimates. Expert consensus — without supporting RCTs — discusses adding hormone therapy rather than adjusting stimulant medication first when perimenopause symptoms persist, and notes that progesterone may antagonize dopamine signaling, which is relevant to progestogen choice (125, 74).
Endometriosis can persist or develop after menopause (postmenopausal prevalence 2-5%) and may itself cause premature or early menopause. In a pooled meta-analysis of 279,948 women across 5 international cohorts, endometriosis was associated with a 7.5-fold higher rate of surgical menopause (HR 7.54), surgical menopause occurring 1.6 years earlier on average, and an OR of 1.36 for spontaneous POI (81).
The EMAS clinical guide frames management differently from standard menopause care: continuous combined estrogen-progestogen therapy is preferred, and estrogen-only therapy is avoided even after hysterectomy — a counter-intuitive exception to standard guidance, because unopposed systemic estrogen is the primary concern for recurrence and malignant transformation. Ovarian cancer absolute lifetime risk increases from 1.3 to 2.5 per 100 women with endometriosis; deep infiltrating endometriosis with endometriomas carries substantially higher risk (81).
T1D adds a distinct metabolic layer to the menopause experience. In a Dutch survey of 159 T1D women, 67.4% reported moderate-to-severe glucose-regulation changes after their final menstrual period — but the direction was heterogeneous, not unidirectional: 41.9% reported higher glucose, 19.6% lower, and 38.5% no change. Both hyperglycemic and hypoglycemic events increased. This was patient-perceived change, not objective CGM/HbA1c data (79).
Disease-specific evidence for HRT in T1D is sparse — only one underpowered trial exists, with no T1D-specific bone, cardiovascular, or sexual-function RCTs. Lipid response to HRT may be blunted in diabetes. VMS and hypoglycemia symptoms can mimic each other, creating real patient burden. The accurate framing is: general-population evidence suggests possible HRT benefits, but T1D-specific evidence is sparse and underpowered, warranting individualized assessment with transdermal estradiol generally considered when HRT is used (101).
Migraine patterns shift during the menopausal transition. Migraine without aura often improves after menopause. Migraine with aura tends to persist and independently increases ischemic stroke and other vascular-event risk. In the NOWAC Norwegian cohort (n=4,825), mean migraine cessation age was 49.7 — close to mean menopause age of 50.1 — but 46.3% continued migraines postmenopause and nearly 1 in 5 still experienced them after age 60. 9.2% reported migraine onset after age 50 (70).
Reviewed guidance generally favors for women with migraine, especially migraine with aura. Oral contraceptives containing estrogen are contraindicated for migraine with aura. Continuous progestogen regimens may reduce withdrawal-related migraine attacks, but this is a progestogen-class statement — the cited micronized-progesterone review found no data on MP's effect on migraine specifically (122, 39). CGRP monoclonal antibodies, gepants, and ditans are effective non-vasoconstrictive alternatives for women with cardiovascular contraindications.
In the largest prospective controlled cohort of BRCA1/2 carriers undergoing risk-reducing salpingo-oophorectomy (WHAM, 104 RRSO + 102 comparators, 24-month follow-up), VMS peaked at 3 months and did not worsen through 24 months. Non-HRT users experienced severe bone loss (lumbar spine -7.8%, total hip -5.2%, femoral neck -6.0%), while HRT users showed substantially mitigated loss (lumbar spine -2.3%, total hip +0.5%). HRT did not prevent or treat depression or anxiety — the authors are explicit on this point (75). In a separate prospective study of 43 BRCA carriers undergoing RRSO (48), sexual function declined significantly, with 66.7% meeting criteria for sexual dysfunction versus 25.4% of controls at 1 year. Testosterone and free androgen index did not correlate with sexual function scores, counter to the common reasoning.
For breast-cancer risk and prior-BC contexts in BRCA carriers, see the Breast Cancer & HRT section — the RRSO-specific MHT guidance here does not replace that section's regimen/endpoint analysis.
In a British Columbia population-based cohort (n=18,676 women aged 50-60 at hysterectomy), bilateral salpingo-oophorectomy at benign hysterectomy did not increase hard cardiovascular events or fractures. However, it increased CVD-predisposing conditions (diabetes aHR 1.36, hypertension aHR 1.10) and doubled HRT initiation (aHR 2.04). Postmenopausal ovaries continue producing androgens that are converted to estrogens — BSO eliminates this residual hormonal contribution (123).
Menopausal biology and needs occur globally. Both evidence quality and access to care differ by population and setting.
The evidence base itself is uneven. A scoping review of 252 studies across 41 low- and middle-income countries found that VMS, joint pain, and sexual concerns appear at rates comparable to high-income countries — but severity and burden data are scarce. Only 4% of studies were nationally representative, only 17.5% used STRAW+10 or WHO menopause criteria, and 85% were cross-sectional. National-level age-at-menopause data are lacking (69).
Provider-initiated conversations are largely absent across cultures. Among 334 African American women, 0% reported their healthcare provider proactively asking about menopause. Mean symptom onset was age 41.5, and 81% reported symptoms lasting 9 or more years. 89% used prayer as a primary coping strategy and 67% used no prescription medications. Among immigrant Muslim women in the UK (n=12), participants reported GP refusal of HRT, limited knowledge about options, and dismissive encounters — but women who did access HRT reported "life-changing benefits." In Nigeria, women frame menopause as requiring endurance rather than care. In Oman, menopause symptoms have culturally specific names — "harara dakhiliya" (internal heat), "kalam mamnoua" (forbidden words) — and CBT was completely absent from all clinical narratives (110, 55, 114, 118).
Access and affordability are structural barriers. Across 6 LMICs studied by the MARIE consortium, HRT formulary availability ranged from 3 of 20 medicines listed (Nepal) to 18 of 20 (Brazil). Availability does not equal affordability: in Nigeria, one combined HRT product cost 260 minimum-wage days for a 2-month supply — 221.52% of annual GNI per capita. BMS guidelines were authored for resource-rich, predominantly Caucasian populations and do not adequately address LMIC realities (128).
South Asian American women in a metro-area cohort (MASALA, n=405) recalled natural menopause at mean age 48 / median 49 — though the authors flag these figures as likely affected by recall bias. 12% reported bothersome hot flashes persisting more than 20 years after menopause. 80% were overweight or obese using Asian-specific BMI cutoffs. The cohort was predominantly Indian-born (82%) and college-educated (88%) — not representative of all South Asian women (59).
Chronic psychosocial stress reframes "culture" as life-course exposure. A US scoping review mapped four stressor domains linked to menopausal experience: socioeconomic position, intimate partner violence and sexual assault/PTSD, childhood abuse and neglect, and racialized stress. The review used intersectionality and life-course frameworks rather than treating menopause as a discrete biological event. Southern US populations — particularly Gulf South low-income and racialized communities — were underrepresented despite high relevance. This was a mapping exercise, not a meta-analysis (41).
What women are looking for online. In a UK survey (n=627), 92.7% used the internet for menopause information, 84.2% as their first source, and 24.4% used the internet only. NHS websites and charities were the most trusted sources; social media was widely used but not trusted. Women with surgical menopause were more likely to search for lubricants, osteoporosis information, and surgical-menopause-specific content — and 23% used a secondary source because online information was missing. 62% of late-perimenopausal women wanted verification of what they found online. The most commonly requested content included comprehensive symptom lists (including atypical symptoms like dental changes, dry eyes, and itchy ears), HRT decision-support tools, treatment alternatives, comorbidity interactions, workplace and family information, and lived-experience narratives (89).
If you cannot use hormone therapy, the evidence shows high symptom burden and low satisfaction with available alternatives (2.0 out of 5 for non-hormonal options versus 3.7 for HT in a qualitative study of 32 HT-unsuitable women, all with moderate-to-severe VMS). Evidence-based non-hormonal options — including CBT-I for insomnia, exercise at specific doses for mood, neurokinin receptor antagonists for hot flashes, and self-administered hypnosis — are covered in the Treatment Options and Vasomotor Symptoms sections (78).
Culturally responsive menopause care requires both communication adaptation and material access. Education alone is insufficient when HRT formulations, trained clinicians, interpretation services, insurance coverage, or affordable supply chains are missing.